[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339403-105":59,"doc-detail-339403-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cxcr4-from-signaling-to-clinical-applications-in-neuroendocrine-neoplasms","CXCR4 - From Signaling to Clinical Applications in Neuroendocrine Neoplasms","","Neuroendocrine neoplasms represent a heterogeneous set of malignant tumors arising from the diffuse endocrine system. Their course is often slow and somatostatin receptor-targeted management is typically used first line, yet high-grade tumors and neuroendocrine carcinomas show poor prognosis with limited benefit from receptor-targeted therapy. This review analyzes CXCR4, a membrane receptor overexpressed in aggressive cancers and linked to worse outcomes, and summarizes current evidence on its diagnostic and therapeutic clinical applications in neuroendocrine neoplasms.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cxcr4-from-signaling-to-clinical-applications-in-neuroendocrine-neoplasms/339403/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cxcr4-from-signaling-to-clinical-applications-in-neuroendocrine-neoplasms/339403.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is CXCR4 considered important in neuroendocrine neoplasms?","Question",{"text":112,"@type":113},"CXCR4 is a membrane receptor known to be overexpressed in aggressive tumors and associated with worse prognosis, while evidence for its use in neuroendocrine neoplasms has been limited—motivating this review.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do CXCL12 and CXCR4 contribute to tumor progression?",{"text":117,"@type":113},"The molecular interaction between CXCL12 and CXCR4 activates intracellular signaling pathways through G proteins, promoting locoregional aggressiveness, EMT, and metastatic appearance.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the aim of this review?",{"text":121,"@type":113},"To focus on current knowledge of the relationship between CXCR4 and neuroendocrine neoplasms, with special emphasis on diagnostic and therapeutic molecular targets.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339403,1790783322,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":14,"preview_urls":146},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","cancers   \nReview  \nCXCR4: From Signaling to Clinical Applications in Neuroendocrine Neoplasms  \nDavid Sanchis-Pascual 1, *, María Isabel Del Olmo-García 1,2, Stefan Prado-Wohlwend 3, Carlos Zac-Romero 4,Ángel Segura Huerta 5, Javier Hernández-Gil 6, Luis Martí-Bonmatí 7 and Juan Francisco Merino-Torres 1,2,8  \nCitation: Sanchis-Pascual, D.; Del Olmo-García, M.I.; Prado-Wohlwend, S.; Zac-Romero, C.; Segura Huerta, Á .; Hernández-Gil, J.; Martí-Bonmatí, L.; Merino-Torres, J.F. CXCR4: From Signaling to Clinical Applications in Neuroendocrine Neoplasms. Cancers 2024, 16, 1799. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/cancers16101799](10.3390/cancers16101799)  \nAcademic Editor: Jose Manuel Lopes  \nReceived: 12 April 2024  \nRevised: 30 April 2024  \nAccepted: 6 May 2024  \nPublished: 8 May 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Endocrinology and Nutrition Department, University and Politecnic Hospital La Fe (Valencia),  \n46026 Valencia, Spain; [delolmo_margar@gva.es](delolmo_margar@gva.es) (M.I.D.O.-G.); [merino_jfr@gva.es](merino_jfr@gva.es) (J.F.M.-T.)  \n2 Joint Research Unit on Endocrinology, Nutrition and Clinical Dietetics, Health Research Institute La Fe, 46026 Valencia, Spain  \n3 Nuclear Medicine Department, University and Politecnic Hospital La Fe (Valencia), 46026 Valencia, Spain; [prado_ste@gva.es](prado_ste@gva.es)  \n4 Patholoy Department, University and Politecnic Hospital La Fe (Valencia), 46026 Valencia, Spain; [zac_carrom@gva.es](zac_carrom@gva.es)  \n5 Medical Oncology Department, University and Politecnic Hospital La Fe (Valencia), 46026 Valencia, Spain; [segura_ang@gva.es](segura_ang@gva.es)  \n6 Instituto de Tecnología Química, Universitat Politècnica de València, Consejo Superior de Investigaciones Científicas, 46022 Valencia, Spain; jahergi@upvnet.upv.es  \n7 Medical Imaging Department, Biomedical Imaging Research Group, Health Research Institute, University and Politecnic Hospital La Fe, 46026 Valencia, Spain; [luis.marti@uv.es](luis.marti@uv.es)  \n8 Department of Medicine, University of Valencia, 46010 Valencia, Spain  \n* Correspondence: sanchis_[davpas@gva.es](davpas@gva.es)  \nSimple Summary: Neuroendocrine neoplasms are a heterogeneous group of malignant tumors that originate from the diffuse endocrine system. They generally have a slow course and somatostatin receptor-targeted based management is the first line of treatment. However, high-grade tumors and neuroendocrine carcinomas have a poor prognosis and somatostatin receptor-targeted therapy is not effective. The membrane receptor CXCR4 has been studied in several neoplasms and it is known to be overexpressed in aggressive tumors and associated with a worse prognosis. However, thereis a lack of evidence of its use in neuroendocrine neoplasms. For that reason, this review describes the significance of CXCR4 and its possible clinical applications in the diagnostic and therapeutic management of neuroendocrine neoplasms.  \nAbstract: There are several well-described molecular mechanisms that influence cell growth and are related to the development of cancer. Chemokines constitute a fundamental element that isnot only involved in local growth but also affects angiogenesis, tumor spread, and metastatic disease. Among them, the C-X-C motif chemokine ligand 12 (CXCL12) and its specific receptor the chemokine C-X-C motif receptor 4 (CXCR4) have been widely studied. The overexpression in cell membranes of CXCR4 has been shown to be associated with the development of different kinds of histological malignancies, such as adenocarcinomas, epidermoid carcinomas, mesenchymal tumors, or neuroendocrine neoplasms (NENs) . The mo","cbCainfcEgeQPQzT","https://ap.wps.com/l/cbCainfcEgeQPQzT","pdf",840613,14,"English","# Simple Summary\n# Abstract\n# Keywords\n# 1. Introduction\n## 1.1. Role of CXCL12 and CXCR4","[{\"question\":\"Why is CXCR4 considered important in neuroendocrine neoplasms?\",\"answer\":\"CXCR4 is a membrane receptor known to be overexpressed in aggressive tumors and associated with worse prognosis, while evidence for its use in neuroendocrine neoplasms has been limited—motivating this review.\"},{\"question\":\"How do CXCL12 and CXCR4 contribute to tumor progression?\",\"answer\":\"The molecular interaction between CXCL12 and CXCR4 activates intracellular signaling pathways through G proteins, promoting locoregional aggressiveness, EMT, and metastatic appearance.\"},{\"question\":\"What is the aim of this review?\",\"answer\":\"To focus on current knowledge of the relationship between CXCR4 and neuroendocrine neoplasms, with special emphasis on diagnostic and therapeutic molecular targets.\"}]","CXCR4 - From Signaling to Clinical Applications in Neuroendocrine Neoplasms | PDF",1790030077,35,[147,151],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/15834a1646a798aaf23dbec3c5c8c328.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/14aec718119014e99cead590fb788b02.webp",982,1388]